Podcasts about mibc

phd md belgium fda keynote md phd christof fda approval keytruda pembrolizumab cisplatin perioperative care mibc

Play Episode Listen Later Dec 31, 2025 8:24

In today's episode, the discussion features Christof Vulsteke, MD, PhD, head of the Integrated Cancer Center Ghent in Belgium, who provided clinical and regulatory insight into the KEYNOTE-905 study (NCT03924895) and the November 2025 FDA approval of enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) for patients with cisplatin-ineligible muscle-invasive bladder cancer (MIBC). In this exclusive interview, Dr Vulsteke outlined the scientific rationale and study design of KEYNOTE-905, reviewed the key efficacy and safety findings observed with the enfortumab vedotin/pembrolizumab combination, and discussed how the safety profile of this combination aligns with prior experience in bladder cancer. He also contextualized the significance of this FDA approval in addressing a longstanding unmet need for cisplatin-ineligible patients and highlighted remaining gaps in care, including global access, patient selection, and future research directions aimed at improving outcomes in this challenging-to-treat population.

ctDNA-Guided Immunotherapy Shows Survival Benefit in MIBC: IMvigor011 Results

Play Episode Listen Later Dec 23, 2025 12:45

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Andrea Necchi, MD Presented at the 2025 ESMO Congress, the IMvigor011 phase 3 trial evaluated a ctDNA-guided strategy for administering adjuvant atezolizumab in patients with muscle-invasive bladder cancer (MIBC) following radical cystectomy. Patients with high-risk pathological features were monitored using a personalized, tumor-informed ctDNA assay; those testing positive for ctDNA were randomized to receive atezolizumab or placebo, while ctDNA-negative patients continued surveillance without treatment. The trial demonstrated significant improvements in both disease-free and overall survival in the atezolizumab group along with favorable outcomes among ctDNA-negative patients, suggesting many may safely avoid overtreatment. Joining Dr. Charles Turck to unpack the study results and how they highlight ctDNA's role in guiding personalized therapy is Dr. Andrea Necchi. Not only is he an investigator on this research, but he's also an Associate Professor of Oncology at Vita-Salute San Raffaele University and the Director of Genitourinary Medical Oncology at IRCCS San Raffaele Hospital and Scientific Institute in Milan, Italy.

director italy patients survival associate professor benefit guided oncology pharmd immunotherapy urology rmd bcps ctdna reachmd oncology and hematology mibc global oncology academy charles turck host charles turck genitourinary medical oncology

MIBC Treatment Landscape

Journal of Clinical Oncology (JCO) Podcast

Play Episode Listen Later Dec 17, 2025 24:27

MIBC Treatment Landscape Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Jen-Jane Liu, MD, FACS CME Available: auau.auanet.org/node/44077 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: AstraZeneca Johnson & Johnson LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Integrate immunotherapy and targeted therapy into the multimodal management of MIBC, selecting appropriate regimens and sequencing strategies based on current guidelines, clinical trial data, and patient-specific factors. 2. Evaluate the clinical role, mechanisms of action, and evidence base for targeted therapies in MIBC, including biomarker-driven selection to support personalized treatment planning. 3. Develop and apply practical approaches for preventing, monitoring, and managing immune-related adverse events and other toxicities associated with immunotherapy and targeted therapy to optimize patient safety, adherence, and quality of life.

phd md treatments develop landscape evaluate integrate mibc

Milan Consensus Endpoints for Bladder Preservation in MIBC

Play Episode Listen Later Dec 11, 2025 27:18

Guests Dr. Andrea Necchi, Dr. Ashish Kamat and host Dr. Davide Soldato discuss JCO article "End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer," focusing on the evolving treatment landscape of MIBC (muscle-invasive bladder cancer) and the need to properly design novel trials investigating non-operative management while including the incorporation of biomarkers and patient perspectives in clinical trials. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today we are joined by JCO authors Andrea Necchi, Associate Professor of Medical Oncology at University San Raffaele and Medical Oncology at Ospedale San Raffaele in Milan, Italy, and Ashish Kamat, Professor of Urologic Oncology and Cancer Research at University of Texas MD Anderson Cancer Center. Both Professor Necchi and Professor Kamat are internationally recognized experts in the field of genitourinary malignancy and particularly in bladder cancer. Today we will be discussing the article titled "Endpoints for the Next Generation Bladder-Sparing Perioperative Trials for Patients with Muscle-Invasive Bladder Cancer." So thank you for speaking with us, Professor Necchi and Professor Kamat. Dr. Andrea Necchi: Thank you, Davide, and thank you JCO for the opportunity. Dr. Ashish Kamat: Yeah, absolutely. It is a great honor and privilege to be discussing this very important article with you. So thank you for the invitation. Dr. Davide Soldato: The article that you just published in JCO reports the results of a consensus meeting that was held among experts in the field of genitourinary malignancy and particularly for bladder cancer. So the objective was really to define endpoints for a novel generation of trials among patients diagnosed with muscle-invasive bladder cancer. So my first question would be: what is the change in clinical practice and in clinical evidence that we have right now that prompted the start of such consensus in 2025? Dr. Andrea Necchi: So, we are living so many changes in the treatment paradigm of patients with muscle-invasive bladder cancer. In general, patients diagnosed with bladder cancer or urothelial cancer today, thanks to the advent of immunotherapy or immunotherapy combinations, and today thanks to the advent of novel antibody-drug conjugates like enfortumab vedotin in combination with immunotherapy that are actually changing the landscape of treatment of patients with metastatic disease and also are entering quite fast into the treatment paradigm of patients with organ-confined disease with a lot of clinical trials testing these combination therapies, neoadjuvantly or adjuvantly, before or after radical cystectomy. Having said that, by potentiating the efficacy of systemic therapy, an increasing number of patients that receive neoadjuvant therapy of any kind, at a certain point in time, result to have achieved a deep response to systemic therapy, evaluated radiologically with conventional imaging, CT scan or MRI, or with cystoscopy or with other urology-based techniques, urinary cytology, and so. And based on the fact that they achieve a complete response, so no residual viable disease after systemic therapy, they raise concern about the fact that they have to undergo surgery like radical cystectomy that is quite impactful for their quality of life and for the future of their lives after the surgery. So the point that the patients are raising, and the patients are raising this point, is primarily due to the efficacy of systemic therapy. And we have seen so many cases fortunately achieving a deep response. So the question about what to do with the patient that at a certain point, at the start with the commitment to radical cystectomy, but at a certain point in time change their mind towards something else if possible, depending on the fact that they have achieved a deep response, is something that is a question and is a need to which we have to provide data, information, and guidance in general to the patients. Dr. Davide Soldato: If we look at the population that the recommendations were formulated for, we are mainly speaking about patients who would be fit for cystectomy, and this is a very distinct population compared to those who are not fit for cystectomy, both from a medical oncology point of view but also from a urologic point of view in terms of surgery. So, can you explain a little bit to our listeners why you think that this distinction is critical and why you developed this recommendation especially for this population? Dr. Ashish Kamat: That is a very important distinction that you made. To build upon what Professor Necchi mentioned earlier, this question that we get from patients after neoadjuvant therapy or systemic therapy is not a new question. It has been something that they have been asking us for the last 20 or 30 years. "Do I really need to have my bladder taken out?" And patients who are especially not fit for surgery will sometimes say, "Do I need to have my bladder taken out? And if I cannot have my bladder taken out, am I going to just not have anything done?" Because the eligibility for radical cystectomy is also a moving target. Over the years with improvement in surgical technique, improvement in perioperative therapy, ERAS protocols, et cetera, it is really unusual for us to deny a patient the opportunity to have major surgery unless clearly they have very significant comorbid conditions. So I think this endeavor is more broadly encompassing of the patient population than what was evident in previous years. And I really want to give a shout out to Professor Necchi because what we did was, as part of the International Bladder Cancer Group and Professor Necchi is an integral part of the scientific advisory board, we broached this topic broadly during one of our discussions. And of course, Andrea always does this, he picks on a topic and then he says, "Okay, we need to discuss this really in detail," put together a multinational, multicenter collaborative group, but the driving force was our patients. Because our patients are constantly asking, "Do I need to lose my organ? Do I need to have radiation therapy?" which again, also, has a lot of side effects. So this was really to answer the question in today's day and age as to do we need to do local consolidation, and if so, in what way? It is not a new question, but we have newer therapies, newer technology, and better ways to answer this. So it is a much needed question that needs to be answered. And I think the distinction between non-surgical candidates and surgical candidates is a little bit blurred in today's day and age. Dr. Davide Soldato: What about the eligibility, for example, for cisplatin-based chemotherapy? Because I think that that is a very fundamental part of this type of strategy that we apply to patients with muscle-invasive bladder cancer. So we know that there are some caveats for proposing such treatment. And also this population was specifically defined inside this recommendation. Dr. Andrea Necchi: I think that the focus of our work is just to analyze what is happening after any type of systemic therapy the patient may get neoadjuvantly. So it is not actually a question of treatment eligibility or including cisplatin eligibility. This is an old question of today's practice and clinical trials. But regardless of what the patient received neoadjuvantly, the point that we have addressed in our consensus meeting was what to do next as a further step after systemic therapy or not. So basically we are- the consensus guidance includes all-comers, so patients to get any type of systemic therapy. So really non-selected based on specific features that determine a special eligibility to a special or a particular therapy. But an all-comer approach is always the winning approach for the translation to be in practice, an all-comer approach just focusing on what has happened after treatment and that we are assessing by the use of conventional imaging, MRI or CT, cystoscopy, urinary cytology, and trying to merge all together this information, all these features in a unique, shared, reliable definition of clinical complete response that could be used as a biomarker for the selection of newer therapies instead of pathological response that has been historically used, and maybe surrogate for the outcome, the long-term outcome and survival of these patients. Dr. Davide Soldato: A very specific point of the consensus was actually the definition of clinical complete response. As you were saying, this is actually a combination of several parameters including urinary cytology, the use of cross-sectional imaging, for example CT scan, but also the evaluation in cystoscopy of the bladder. Do you foresee any potential problems when applying this type of recommendation, not inside clinical trials, but in the context of routine clinical practice? Dr. Ashish Kamat: Absolutely. And that was the whole reason we had this consensus meeting. What happens nowadays in daily practice, and we see this every day at our center, we see patients referred to us. This definition or this sort of attempt to define clinical complete response is an ongoing issue. And urologists, medical oncologists, radiation oncologists are always looking to see, does my patient have a complete response? That definition and those paradigms have changed and evolved over the years. The FDA had a workshop many years ago looking at this very question. And it was to address the proposal that complete clinical response, which is a clinical definition, a clinical state, does this correlate with pathologic response? And with the technology and the systemic therapies we had then, the answer was 'no'. In fact, more patients got recurrent disease than did not get recurrent disease. And that is why, of course in the paper we mention the trials that looked at this question, the trials that evolved around this question. And I think the distinction between a clinical trial and daily practice is extremely important when we are looking at this definition per se. Because essentially what happens with this issue is that if the patient is not appropriately counseled, and if the physician does not do the appropriate clinical complete response assessment as Professor Necchi mentioned, right, cystoscopy, cytology, imaging, use of markers that are still in evolvement, we risk doing harm to the patient. So we caution in the paper too that this definition is not ready for prime time use. It is something that needs to be studied. It is a rigorous definition and currently we are recommending it for clinical trials. I am sure eventually it will trickle down into clinical practice, but that guidance was not the purpose of this consensus meeting. Dr. Davide Soldato: There are several parameters that are potentially evolving and could potentially enter inside of clinical practice. For example, you mentioned pelvic MRI and we have now very specific criteria, the VI-RADS criteria, we're able actually to diagnose and also to provide information. So along with these novel imaging techniques, we also know that there are novel biomarkers that could be explored, for example ctDNA and urinary DNA. So what I was wondering is, why were not these included inside the definition that you provide for clinical complete response? And do you think that, as we are designing these trials to potentially spare cystectomy for this patient, we should include these biomarkers very early so that we can actually provide better stratification for our patients and really propose this type of cystectomy-sparing strategy only to those where we are very confident that we have obtained a clinical complete response? Dr. Andrea Necchi: I would say you have just to wait. So a follow-up is ongoing and hard work is ongoing. At the time we met, at the time we established the meeting in mid-December last year, we had no information on the ctDNA data from major trials, with only a few exceptions. So we were just at the beginning of a story that was more than likely to change but still without numbers and without data from clinical trials. Now in just nine months or 10 months time, we have accumulated important data and newer data will be presented during just a few weeks and a few days regarding the ctDNA, circulating tumor DNA in particular, as a prognostic marker assessed baseline or assessed after neoadjuvant therapy. So the point is certainly well made and ctDNA is certainly well shaped to be incorporated in a future definition of clinical complete response. But you have to consider the fact that most of the data that we are accumulating related to ctDNA are about the post-cystectomy field or the metastatic field. So regarding neoadjuvant therapy, you know, we have neoadjuvant therapy in the context of bladder-sparing approach, basically we have no information. And the point that is emerging in our daily practice when using these biomarkers or in clinical trials, and the impression in general, is that it is a very strong biomarker associated with survival, but we absolutely do not know what is the performance of the test in the prediction of superficial bladder relapses, high-grade pTa relapse in the bladder that is left untouched in the patient. We are considering, and maybe it will be just a matter of further discussion, not just what is happening within the immediate endpoint of clinical CR, but also what is happening later with other survival endpoints. And for example, when looking at the type of events that we may see in this kind of bladder-sparing approaches, most of the events, also in the trials that have been published including the RETAIN study published in JCO, most of the events are related to superficial high-grade superficial non-muscle invasive relapses. So the ability to predict these types of events with ctDNA is completely unknown. Maybe, maybe other liquid biomarkers like urinary tumor DNA, utDNA, could be a bit better shaped in the prediction of this kind of events, you know. But we have still to build the story. So the question is good. The answer is yes, we will likely, more than likely incorporate liquid biomarkers in the definition, but we have to wait at least more data and more robust data in order to translate this information in routine practice, you know. Another consensus meeting is organized by IBCG and the same folks for November. This meeting will be primarily focused on the liquid biomarkers, the interpretation and use and approval and so of liquid biomarkers including bladder cancer. And we will likely be able to address all these, most of these open issues, so most of these points in the next meetings. Dr. Davide Soldato: In the consensus you say that probably clinical complete response is now ready to be included in early phase trials, so actually to test what is the efficacy of the regimens that is being evaluated inside of these trials. But you actually do very in-depth work of defining what are the most appropriate endpoints for later phase trials. So to be very specific, the phase three registrational trials that bring new regimens inside of this space. So I just wanted to hear a little bit about what was the definition for event-free survival, which you define as the most appropriate one for this type of trials. And as you were mentioning before, Professor Necchi, there is a very specific interest on the type of events that we observe, especially when we look at these superficial relapses inside of the bladder. So was this a very urgent matter of debate as we define which type of events should actually trigger event-free survival? And did you make a very thoughtful decision about why using this type of endpoint instead of others, for example metastasis-free survival? Dr. Ashish Kamat: Yeah, this was a matter of intense debate as you might imagine. And again, this is a moving target. So as Professor Necchi mentioned, we tend to partner with each other, our organizations, on having definitions of clinical complete response, biomarker, retreats, and then using that as a marker, and you might imagine this definition of what is appropriate event-free survival, what events matter to the patient, is something we have been talking about for two years. It was not just something that came up at the retreat. But at the retreat there was intense discussion. One of the things that we talked about was bladder-intact event-free survival because we are trying to spare the patient's bladder. And do we count bladder-intact event-free survival as something that is relevant? The patient advocates absolutely liked that, right? They wanted that. But then we also learned from some of the studies, for example from the RETAIN study, that the non-muscle invasive recurrences can actually lead to metastatic disease. It is not as benign when you have a patient with muscle-invasive bladder cancer that then develops a non-invasive tumor because maybe there is cancer growing underneath the surface that we don't detect when we look in the bladder. So a lot of those discussions were held, debated. It was a consensus. I have to say it was not 100% agreement on that particular definition, but it was broad consensus. And Andrea, do you want to clarify a little bit as to how we came about that consensus? Because I think this is a very important point we need to make. Dr. Andrea Necchi: We focused on a bit different definition of BI-EFS, Bladder-Intact Event-Free survival. Just stating EFS as an all-inclusive parameter including all type of high-grade relapse or progression or death that may happen to the patient. So that we were counting high-grade pTa, pT1, CIS relapses to the bladder and of course more deeper involvement in the muscle layer and so, and metastatic disease as a relapse. But the point is that as compared to the classical bladder-intact EFS definition of chemoradiation bladder-sparing approaches that is including muscle-invasive relapses only or death as events, we tried to be as inclusive as possible in order to be as much conservative as possible and to raise as higher the bar as possible for the success. And this is actually what the patients are asking us. So they are asking, "Okay, I can save my bladder, sparing radical cystectomy, but at which cost?" So in order to provide an answer, we have to be very, very cautious and be on the right shape, on the right position to say, "Okay, we have accomplished the most, the safest points, you know, by which you can proceed with the bladder-sparing." This is the first point. The other point is related to the MFS, metastasis-free survival that you have mentioned. For sure, it was recognized as a very important point for sure. But in the discussion was clear that our focus was in saving patients, curing the patient, and saving the bladder. Any single event, superficial event that may occur in the bladder-saving approaches of this kind may expose the patient to an extra risk of developing distant metastases, as it happened for example in the RETAIN study. So EFS defined as we have agreed and published, is actually a way of including or anticipating in a safest position the MFS. Because most or if not the entirety of the events of metastasis development in patients undergoing bladder-sparing after neoadjuvant systemic therapy were preceded by a superficial phase of disease relapse, you know. So I remember very, very few, or we can count just on the finger of one hand, the cases that have been reported in the literature developing de novo metastatic disease in the similar bladder-sparing approaches, in particular when using a maintenance immunotherapy strategy, you know, after they reach TURBT. So this is the reason why with all the limitation that Ashish has mentioned, with all the uncertainties that are still there, the nervousness that is still there, EFS, as defined in the protocol, as put in the paper, is to us at the moment is the safest way to use a primary endpoint in potentially registration trials of this kind with perioperative systemic therapy and response-adapted surgery. Dr. Ashish Kamat: And David, just to be absolutely clear for our listeners, right, so what was the event-free survival that we defined? Essentially it was a very inclusive definition. Event was defined as high-grade tumor persistence, recurrence, or progression during or after perioperative therapy, and receipt of any additional standard of care treatment including radical cystectomy, radiotherapy or even intravesical therapy. So this was done at the behest of our patient advocates because we really wanted to make a very robust definition that could be utilized appropriately as an adequate primary endpoint for both early and late phase bladder preservation trials. Dr. Davide Soldato: I think that it really highlights one of the points that I liked the most about this consensus is that it really incorporated the patient vision and a sort of shared decision making process when we are deciding how we want to design these trials that will explore this bladder-sparing surgery. And Professor Necchi mentioned something that I think will be also a very interesting question for trials that will be developed considering the activity of this combination that we are seeing right now, which is maintenance. Because right now our approach in the few cases where patients do not do any type of treatments after an induction with neoadjuvant treatments is basically represented by observation. So I was wondering if you think that the field will actually evolve to a sort of maintenance strategy even in patients that will achieve a complete clinical response? Dr. Andrea Necchi: We just mentioned briefly in the paper, this is a very important point that was touched during the discussion, and in particular was raised and discussed by FDA people participating in the meeting. And when looking at the data from the trials that were available and are still available thus far, we could provide a suggestion that maintenance immune therapy is the preferred approach in this kind of approach as it currently stands, as the data currently stand. Because the cleanest data towards the successful part of this journey is related to the studies that provided a kind of maintenance therapy, like the study with nivolumab or the RETAIN-2 study with maintenance immune therapy instead of RETAIN study that was just stopping treatment until surgery with MVAC chemotherapy. So in general the impression is that maintenance therapy may help in reducing the type of events, including the events that we incorporate in the EFS definition that we mentioned in the paper. The point that you mentioned is very important because on the other side we have a problem, a big problem of affordability and cost of the treatment. The de-escalation trials are an urgent need and represent a call for the studies. Unfortunately, as you mentioned, this is something that moves beyond the possibilities of this type of consensus because we don't have data and we have to accumulate data from clinical trials prior to saying, "Okay, certain patients could de-escalate therapy and stop therapy and some other not." So we are still at the very beginning. So we can do- we can discuss about this in the radical cystectomy paradigm but not in the bladder-sparing paradigm, you know. But this is for sure a point, a discussion point that will be taken, pretty well taken in one year or two year projection. Dr. Davide Soldato: I was wondering if in the consensus, considering that patient advocates and patient associations were also involved, did you decide to actually suggest the inclusion of patient-reported outcomes or the evaluation of shared decision-making in the development of this trial really as endpoints that should matter as much or as much as possible as event-free survival and clinical complete response? Dr. Ashish Kamat: Oh yeah, absolutely. We had patient advocates, we had the World Bladder Cancer Patient Coalition, Bladder Cancer Advocacy Network, patient representatives. And we always consider this. Shared decision-making is actually the impetus behind why these efforts have been launched, right? So it is the shared decision-making that is very, very important. It is the driving force behind what we do. And it is worth noting, for example, for the design of such studies, regulatory agencies consider response-based endpoints or overall survival as primary endpoints. But the patient advocates consider quality of life to be just as important, if not more important sometimes than overall survival numbers. Because patient advocates will say, "Well if I live longer but I'm miserable living longer, yes that works for regulatory agencies but doesn't work for us." So PROs clearly are very, very important. And, in fact, we just literally had a meeting in Houston, the IBCG meeting where PROs were a main point of what we discussed. So incorporating PROs in everything we do, not just this but everything we do, Dr. Necchi, myself, everybody involved in these fields realizes it is very, very important. So absolutely. Dr. Davide Soldato: I want to thank again Professor Necchi and Professor Kamat for joining us today. Dr. Andrea Necchi: Thank you. Dr. Ashish Kamat: It is our pleasure. Dr. Davide Soldato: Thanks again and we appreciate you sharing more on your JCO article titled "Endpoints for the Next Generation Bladder-Sparing Perioperative Trials for Patients with Muscle-Invasive Bladder Cancer." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Episode 467: The Uromigos Score for MIBC and Advanced Urothelial Cancer

cancer score bladder cancer mibc

Play Episode Listen Later Dec 9, 2025 37:52

Matt Galsky joins to discuss the latest iteration of the Uromigos Score in Bladder Cancer. This score quantifies the clinical value of various approaches across several disease states. 30 global experts score each approach.

EMUC25 special: Prof. Dyrskjøt talks about ctDNA in MIBC

Play Episode Listen Later Nov 21, 2025 12:00

UROONCO BCa associate edtiors Dr. Laura Mertens (NL) and Dr. Elisabeth Grobet-Jeandin (CH) talked to Prof. Lars Dyrskjøt (DE) about ctDNA in muscle invasive bladder cancer. To conclude this discussion, the associate editors also prepared some insightful rapid fire questions for Prof. Dyrskjøt.This interview was recorded at EMUC25 in Prague. For more updates on bladder cancer, please visit our educational platform UROONCO BCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

spotify prof prague eau ctdna mibc

ESMO 2025 special: Prof. Vulsteke presents KEYNOTE-905/EV303 study results

Play Episode Listen Later Oct 22, 2025 13:08

UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks to Prof. Christof Vulsteke (BE) on the design and results of the phase III KEYNOTE 905/EV303 study: Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible. This interview was recorded at ESMO 2025 in Berlin, Germany. For more updates on bladder cancer, please visit our educational platform UROONCO BCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

spotify germany study berlin prof ev keynote urology eau perioperative bladder cancer esmo mibc

Episode 448: Neoadjuvant EV/Pembro in Cis-ineligible MIBC

SBS Hakha Chin - SBS Hakha Chin

Play Episode Listen Later Oct 18, 2025 46:21

Christof Vulsteke joins Brian and Tom to discuss his practice-changing data on neoadjuvant EVP in MIBC. More applause!!

evp neoadjuvant mibc

MIBC khrihfabu kum hra tlin le biakinn luh lawmhnak

Play Episode Listen Later Oct 13, 2025 6:22

Australia ramchung, Melbourne ah hram a bunhmi MIBC khrihfabu nih biakinn an cawk. Melbourne Immanuel Baptist Church (MIBC) cu 2015 ah an rak dirhmi khrihfabu a si. Kum hra tiang Pathian nih lam a hruai hna lawng siloin biakinn luhnak zong tlamtling tein an tuah khawh.

australia melbourne kum mibc pathian

AMJ Podcast | Episode 2: Inside the MDT: Expert Voices in Muscle-Invasive Bladder Cancer Care

The EMJ Podcast: Insights For Healthcare Professionals

Play Episode Listen Later Oct 3, 2025 38:53

This content was funded by AstraZeneca, and is intended for US Healthcare Professionals. How do urologists, oncologists, and advanced practice providers coordinate care in muscle-invasive bladder cancer (MIBC)? This AMJ podcast brings together three leading experts in each speciality to explore best practices in MDT collaboration, patient transitions, and treatment strategy. Listen now to strengthen your approach to MIBC care. Chapters: 00:00 – 02:18 | Introductions 02:18 – 10:15 | MDT Collaboration & Best Practices 10:15 – 16:16 | Patient Pathway & Coordination 16:16 – 25:23 | Treatment Decisions & Strategy 25:23 – 33:38 | Immune-Mediated AR Management 33:38 – 38:52 | Key Takeaways Speakers: Chandler Park, MD – Medical Oncologist, Norton Cancer Institute; & Clinical Faculty, University of Louisville School of Medicine Gautam Jayram, MD – Urologist, Urology Associates, Nashville, TN Michael White, PA-C – Physician Assistant, Urology Partners of North Texas

university nashville voices chapters muscle astrazeneca north texas invasive cancer care mdt bladder cancer louisville school clinical faculty mibc

The OncoAlert Weekly RoundUp September 12-18, 2025: PRIME | NECTIN-4 | PREOPANC-2 | WU-KONG1B & More

OncoAlert

Play Episode Listen Later Sep 19, 2025 5:52

The OncoAlert Weekly Roundup is your go-to podcast for the latest, most impactful updates in oncology from across the globe

nurses prime mri weekly roundup egfr adcs mibc

Contemporary Management of MIBC and Beyond: Expert Guidance for Urologists (Republished)

management guidance pfizer contemporary utilize analyze employ cme urologists republished astellas mibc

Play Episode Listen Later Aug 6, 2025 69:56

Contemporary Management of MIBC and Beyond: Expert Guidance for Urologists (Republished) CME Available: auau.auanet.org/node/42040 After participating in this CME activity, participants will be able to: 1. Describe the multimodal treatment approach for MIBC, including surgery, radiation therapy, and chemotherapy. 2. Analyze the role of neoadjuvant and adjuvant therapies, including chemotherapy, immunotherapy, and antibody drug conjugates, in improving patient outcomes. 3. Utilize knowledge of checkpoint inhibitors and antibody drug conjugates with their mechanisms of action to interpret the role of immunotherapy in the treatment of metastatic urothelial carcinoma. 4. Examine ongoing clinical trials and emerging treatments that are shaping the future of metastatic urothelial carcinoma management. 5. Employ appropriate patient and family education strategies regarding MIBC and metastatic urothelial carcinoma, treatment options, and expected outcomes. Acknowledgements Support provided by an independent educational grant from: Astellas and Pfizer, Inc.

S13 Ep6: FDA Approval Insights: Perioperative Durvalumab Plus Chemo in MIBC: With Matthew Galsky, MD

Oncology for the Inquisitive Mind

Play Episode Listen Later May 28, 2025 7:48

In today's episode, we spoke with Matthew Galsky, MD, about the FDA approval of neoadjuvant durvalumab (Imfinzi) plus gemcitabine and cisplatin followed by adjuvant durvalumab monotherapy after radical cystectomy for the treatment of adult patients with muscle-invasive bladder cancer (MIBC). Dr Galsky is a professor of medicine (hematology and medical oncology), a professor of urology, director of Genitourinary Medical Oncology, co-director of the Center of Excellence for Bladder Cancer, and director for Translational Research at The Tisch Cancer Institute in New York, New York. In our exclusive interview, Dr Galsky discussed the significance of this approval, key efficacy and safety data from the pivotal phase 3 NIAGARA trial (NCT03732677), and the role of this regimen in the MIBC treatment paradigm, including for cisplatin-eligible patients with mild renal impairment.

new york md excellence fda niagara chemo fda approval perioperative translational research bladder cancer mibc genitourinary medical oncology

Trump Pausa Aranceles, Tesla Cae en Europa y WeRide se Expande a Arabia Saudita.

WALL STREET COLADA

Play Episode Listen Later May 27, 2025 4:19

En este episodio cubrimos los eventos más relevantes antes de la apertura del mercado: • Wall Street sube por pausa arancelaria de Trump: Futuros al alza: $SPX +1.6%, $US100 +1.7%, $INDU +1.4%. Trump retrasa aranceles del 50% a la UE hasta el 9 de julio, lo que alivia el sentimiento del mercado tras una semana negativa. Hoy se publican pedidos de bienes duraderos de abril (estimado: -7.6%) y núcleo (-0.1%), además de la confianza del consumidor de mayo (previsto: 87.1). También se esperan los precios de viviendas S&P Case-Shiller y FHFA. Atentos al reporte de $NVDA este miércoles. • Tesla se desploma en Europa: $TSLA vendió solo 7,261 vehículos eléctricos en abril en Europa (-49% YoY), mientras el sector creció 34.1%. La marca pierde terreno por la controversia política de Musk, el auge de los híbridos (35% del mercado) y la competencia feroz de BYD y otros fabricantes. A pesar de ello, las acciones suben +2.7% premarket. • WeRide acelera en Medio Oriente: $WRD anunció su expansión a Arabia Saudita, con planes de lanzar robotaxis en Riad y AlUla en alianza con la Autoridad General de Transporte. La operación se integrará a la app de $UBER y se espera el despliegue completo para fines de 2025. La empresa también amplía su red a 15 ciudades más junto a $UBER en los próximos cinco años. $WRD +5.7% premarket a $9.63. • AstraZeneca avanza con Imfinzi en cáncer de vejiga: $AZN recibió respaldo positivo del panel de la EMA para su inmunoterapia Imfinzi en combinación con quimioterapia para tratar el MIBC resecable. El estudio fase 3 NIAGARA mostró beneficios en supervivencia libre de eventos y general. Se espera la decisión final de la Comisión Europea. Una jornada con alivio geopolítico, expansión tecnológica y avances farmacéuticos. ¡No te lo pierdas!

157. Back to Basics - Early Bladder Cancer

Play Episode Listen Later May 24, 2025 19:05

This week, we explore muscle-invasive bladder cancer (MIBC). This space has made significant progress with the completion of two pivotal trials. The first was VESPER, comparing two chemotherapy regimens. The key to this trial may be the amount of cisplatin delivered, but there are some unknowns in a real-world setting. It also compared the neoadjuvant to the perioperative space. The second trial utilises immunotherapy in the perioperative landscape and is the first trial to so but only used one chemotherapy regimen.A must-listen to episode comparing the complexities of early bladder cancer and the options available.Studies discussed in the episode:VESPERNIAGARAFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

studies acast pfizer back to basics oncology complease vesper bladder cancer comart mibc

Expert discussion: 2025 EAU Guidelines updates for MIBC

Play Episode Listen Later May 17, 2025 15:09

The panel chair of the EAU guidelines on MIBC, Assoc. Prof. A. Van Der Heijden discusses the new updates with panel members Dr. L. Mertens and Prof. P. Mariappan.You can view the newest Muscle-invasive and Metastatic Bladder Cancer EAU Guidelines, or download EAU Guidelines App. The app helps to optimise your search with interactive tools to quickly get the answer you need from the best-practice clinical guidelines for urologists. EAU members get full access, and non-members can explore with a 30-day free trial.

prof muscle guidelines assoc urology eau mertens bladder cancer mibc

AUA 2025 special: Dr. Guerrero-Ramos shares first results of SunRISe-1 cohort 4

spotify las vegas bond ramos sunrise guerrero tar annual meetings cohorts bcg urology eau bladder cancer american urological association mibc

Play Episode Listen Later May 8, 2025 7:41

At the American Urological Association's 2025 Annual Meeting in Las Vegas, Dr. Félix Guerrero-Ramos (ES) presented the first results from cohort 4 of the SunRISe-1 study, assessing TAR-200 monotherapy in patients with Bacillus Calmette-Guérin (BCG) - unresponsive papillary-only high-risk non-muscle-invasive bladder cancer.In this episode, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) interviews Dr. Guerrero-Ramos about the study's design, a detailed discussion of the results, comparisons with other trials such as BOND-003, and the implications for clinical practice. For more updates on bladder cancer, please visit our educational platform UROONCO BCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Genitourinary Cancers — An Interview with Dr William K Oh on Recent Trial Updates

Play Episode Listen Later Apr 23, 2025 44:21

Featuring an interview with Dr William K Oh, including the following topics: Use of secondary hormonal agents for patients with metastatic hormone-sensitive prostate cancer (0:00) Data supporting the clinical activity of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) (11:10) Radiopharmaceuticals for the treatment of mCRPC (16:53) Available data on cabozantinib for mCRPC (24:38) Cabozantinib combinations for advanced renal cell carcinoma (RCC) (26:17) Subcutaneous nivolumab versus intravenous nivolumab for advanced RCC (30:00) Addition of nivolumab to tivozanib compared to tivozanib alone in advanced relapsed/refractory RCC previously treated with an immune checkpoint inhibitor (31:28) Long-term follow-up with belzutifan for relapsed/refractory advanced RCC (33:39) Major findings from the NIAGARA study of perioperative durvalumab for muscle-invasive bladder cancer (MIBC) (35:44) Data surrounding adjuvant immunotherapy for MIBC (38:07) Clinical development of TAR-200 for high-risk non-muscle-invasive bladder cancer (39:44) Updated analysis of EV-302 study of enfortumab vedotin in combination with pembrolizumab for previously untreated advanced urothelial cancer (UC) (41:06) Implementation of emerging data in the treatment landscape of UC (41:56) CME information and select publications

data cancer trial ev clinical implementation addition uc tar niagara cme rcc parp subcutaneous genitourinary mibc cabozantinib william k oh

S12 Ep37: Bladder-Sparing Strategies and ctDNA-Guided Strategies Take Center Stage in MIBC: With Chandler Park, MD; and Vadim Koshkin, MD

walking medicine vaccines treatments fda approved pharma improves pharmaceuticals semaglutide chlamydia gonorrhea hemophilia bladder cancer mpr weekly dose prader willi syndrome trichomoniasis mibc

Play Episode Listen Later Apr 14, 2025 5:28

In this week's episode of MedNews Week's Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, concluded a 3-part series with Vadim Koshkin, MD, an associate professor of medicine in the Division of Hematology and Oncology in the Department of Medicine at the University of California, San Francisco (UCSF) School of Medicine, as well as a genitourinary medical oncologist at the UCSF Helen Diller Comprehensive Cancer Center. In part 3 of this 3-part episode series, Drs Park and Koshkin explored the clinical implications of practice-changing data from the phase 3 NIAGARA trial (NCT03732677) of perioperative durvalumab plus neoadjuvant chemotherapy in patients with resectable bladder cancer and discussed how the evolving perioperative treatment paradigm may affect future treatment sequencing decisions for this population. Additional topics included ongoing research efforts focused on bladder-sparing strategies, the utility of circulating tumor DNA and advanced imaging to guide treatment intensity, and the role of biomarker-driven approaches to personalize therapy for patients with muscle-invasive disease.

university california strategy dna medicine kentucky park md louisville guided oncology center stage niagara bladder hematology vadim sparing ctdna mibc

MPR Weekly Dose Podcast #231 — Treatment for hyperphagia in Prader-Willi Syndrome; Qfitlia Approved; Chlamydia Vaccine and OTC Test; Semaglutide Improves Walking; Imfinzi Approved for MIBC

MPR Weekly Dose

Play Episode Listen Later Apr 4, 2025 16:59

New treatments for Prader-Willi Syndrome and hemophilia; FDA fast tracks a chlamydia vaccine candidate; over-the-counter test cleared for identifying chlamydia, gonorrhea and trichomoniasis; semaglutide improves walking ability in patients with peripheral artery disease; and Imfinzi combo therapy approved for MIBC.

Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management

guidelines antibodies cme adverse urology aes event management rmd mbc bladder cancer antibody drug conjugates reachmd cme/ce oncology and hematology mibc

Play Episode Listen Later Mar 26, 2025

CME credits: 0.50 Valid until: 26-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/antibody-drug-conjugates-in-bladder-cancer-guideline-updates-and-adverse-event-management/29174/ New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide management strategies for common AEs seen with newer immunotherapy.=

Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management

guidelines antibodies cme adverse urology aes event management rmd mbc bladder cancer antibody drug conjugates reachmd cme/ce oncology and hematology mibc

Play Episode Listen Later Mar 26, 2025

CME credits: 0.50 Valid until: 26-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/antibody-drug-conjugates-in-bladder-cancer-guideline-updates-and-adverse-event-management/29174/ New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide management strategies for common AEs seen with newer immunotherapy.=

Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management

ms md guidelines antibodies adverse urology aes event management rmd mbc bladder cancer antibody drug conjugates reachmd cme/ce oncology and hematology mibc

Play Episode Listen Later Mar 26, 2025

Host: Elizabeth R. Plimack, MD, MS, FASCO Guest: Shilpa Gupta, MD New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide management strategies for common AEs seen with newer immunotherapy.

Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management

ms md guidelines antibodies adverse urology aes event management rmd mbc bladder cancer antibody drug conjugates reachmd cme/ce oncology and hematology mibc

Play Episode Listen Later Mar 26, 2025

Host: Elizabeth R. Plimack, MD, MS, FASCO Guest: Shilpa Gupta, MD New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide management strategies for common AEs seen with newer immunotherapy.

S12 Ep25: Perioperative Durvalumab Improves Survival in MIBC: Navigating the NIAGARA Trial Findings With: Chandler Park, MD; and Petros Grivas, MD, PhD

Play Episode Listen Later Mar 12, 2025 23:04

In this episode of MedNews Week's Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, spoke with Petros Grivas, MD, PhD, clinical director of the Genitourinary Cancers Program at Fred Hutchinson Cancer Center and a professor of medicine at the University of Washington School of Medicine, about key updates from the 2025 Genitourinary Cancers Symposium and the evolving treatment paradigm for muscle-invasive bladder cancer (MIBC).

university navigating phd medicine kentucky trial park md survival louisville findings improves niagara md phd washington school petros perioperative mibc genitourinary cancers symposium

S12 Ep18: Neoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD

Play Episode Listen Later Feb 26, 2025 20:33

In this episode of Oncology Unplugged, a podcast series from OncLive and MedNews Week, podcast host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD, to talk about a pilot trial investigating neoadjuvant accelerated methotrexate, vinblastine,doxorubicin, and cisplatin (aMVAC) plus pembrolizumab (Keytruda) in patients with non-urothelial muscle-invasive bladder cancer, findings from which were presented at the 2025 Genitourinary Cancers Symposium. Dr Grivas is clinical director of the Genitourinary Cancers Program and a professor in the Clinical Research Division at Fred Hutchinson Cancer Center, as well as a professor in the Division of Hematology and Oncology at the University of Washington School of Medicine in Seattle. Dr Raychaudhuri is an assistant professor in the Clinical Research Division at Fred Hutchinson Cancer Center, as well as an assistant professor in the Division of Hematology and Oncology at the University of Washington School of Medicine. In their exclusive conversation, Drs Park, Grivas, and Raychaudhuri discussed key efficacy and safety findings from this study; the need for conducting dedicated research in bladder cancer patient populations with variant histologies; and the potential of biomarkers, such as HER2 expression, to improve the bladder cancer treatment paradigm in the future.

university phd seattle medicine kentucky park md louisville unprecedented oncology md phd generates hematology washington school petros her2 neoadjuvant keytruda pembrolizumab mvac mibc genitourinary cancers symposium clinical research division onclive

Reviewing the Latest Bladder Cancer Practice Guidelines

reviewing cme aes rmd mbc bladder cancer practice guidelines reachmd cme/ce oncology and hematology mibc

Play Episode Listen Later Feb 21, 2025

CME credits: 0.50 Valid until: 21-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/reviewing-the-latest-bladder-cancer-practice-guidelines/32675/ New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.

Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer

treatments emerging muscle invasive cme aes rmd mbc bladder cancer reachmd cme/ce oncology and hematology mibc

Play Episode Listen Later Feb 21, 2025

CME credits: 0.50 Valid until: 21-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/exploring-new-and-emerging-treatments-in-muscle-invasive-bladder-cancer/32676/ New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.

Patient Perspectives on Bladder Cancer

patients cme aes rmd mbc bladder cancer patient perspectives reachmd cme/ce oncology and hematology mibc

Play Episode Listen Later Feb 21, 2025

CME credits: 0.50 Valid until: 21-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/patient-perspectives-on-bladder-cancer/32677/ New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.

Patient Perspectives on Bladder Cancer

patients cme aes rmd mbc bladder cancer patient perspectives reachmd cme/ce oncology and hematology mibc

Play Episode Listen Later Feb 21, 2025

CME credits: 0.50 Valid until: 21-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/patient-perspectives-on-bladder-cancer/32677/ New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.

Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer

treatments emerging muscle invasive cme aes rmd mbc bladder cancer reachmd cme/ce oncology and hematology mibc

Play Episode Listen Later Feb 21, 2025

CME credits: 0.50 Valid until: 21-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/exploring-new-and-emerging-treatments-in-muscle-invasive-bladder-cancer/32676/ New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.

Reviewing the Latest Bladder Cancer Practice Guidelines

reviewing cme aes rmd mbc bladder cancer practice guidelines reachmd cme/ce oncology and hematology mibc

Play Episode Listen Later Feb 21, 2025

CME credits: 0.50 Valid until: 21-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/reviewing-the-latest-bladder-cancer-practice-guidelines/32675/ New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.

Patient Perspectives on Bladder Cancer

ms patients md msn aes rmd mbc bladder cancer patient perspectives reachmd cme/ce oncology and hematology mibc

Play Episode Listen Later Feb 21, 2025

Host: Elizabeth R. Plimack, MD, MS, FASCO Guest: Lillibeth Velasco, MSN, RN New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.

Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer

Play Episode Listen Later Feb 21, 2025

Host: Elizabeth R. Plimack, MD, MS, FASCO New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.

ms md treatments emerging muscle invasive aes rmd mbc bladder cancer reachmd cme/ce oncology and hematology mibc

Patient Perspectives on Bladder Cancer

ms patients md msn aes rmd mbc bladder cancer patient perspectives reachmd cme/ce oncology and hematology mibc

Play Episode Listen Later Feb 21, 2025

Host: Elizabeth R. Plimack, MD, MS, FASCO Guest: Lillibeth Velasco, MSN, RN New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.

Reviewing the Latest Bladder Cancer Practice Guidelines

ms md reviewing aes rmd mbc bladder cancer practice guidelines reachmd cme/ce oncology and hematology mibc

Play Episode Listen Later Feb 21, 2025

Host: Elizabeth R. Plimack, MD, MS, FASCO New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.

Reviewing the Latest Bladder Cancer Practice Guidelines

ms md reviewing aes rmd mbc bladder cancer practice guidelines reachmd cme/ce oncology and hematology mibc

Play Episode Listen Later Feb 21, 2025

Host: Elizabeth R. Plimack, MD, MS, FASCO New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.

Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer

Play Episode Listen Later Feb 21, 2025

Host: Elizabeth R. Plimack, MD, MS, FASCO New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.

ms md treatments emerging muscle invasive aes rmd mbc bladder cancer reachmd cme/ce oncology and hematology mibc

Episode 387: ASCO GU 2025 -Neoadjuvant Disitamab Vedotin + Toripalimab in HER2+ MIBC: updated efficacy and safety results

Play Episode Listen Later Feb 14, 2025 27:07

Xinan Sheng. M.D., Professor in the Department of Genitourinary Oncology at Peking University Cancer Hospital &institute in Beijing, China joins us to discuss the update of this trial and impressive pCR rates.

china professor safety beijing pcr efficacy her2 neoadjuvant asco gu mibc

Contemporary Management of MIBC and Beyond: Expert Guidance for Urologists

management guidance pfizer contemporary utilize analyze employ cme urologists astellas mibc

Play Episode Listen Later Dec 18, 2024 70:13

Contemporary Management of MIBC and Beyond: Expert Guidance for Urologists CME Available: https://auau.auanet.org/node/42040 After participating in this CME activity, participants will be able to: 1. Describe the multimodal treatment approach for MIBC, including surgery, radiation therapy, and chemotherapy. 2. Analyze the role of neoadjuvant and adjuvant therapies, including chemotherapy, immunotherapy, and antibody drug conjugates, in improving patient outcomes. 3. Utilize knowledge of checkpoint inhibitors and antibody drug conjugates with their mechanisms of action to interpret the role of immunotherapy in the treatment of metastatic urothelial carcinoma. 4. Examine ongoing clinical trials and emerging treatments that are shaping the future of metastatic urothelial carcinoma management. 5. Employ appropriate patient and family education strategies regarding MIBC and metastatic urothelial carcinoma, treatment options, and expected outcomes. Acknowledgements Support provided by an independent educational grant from: Astellas and Pfizer, Inc.

S11 Ep32: Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

Play Episode Listen Later Nov 6, 2024 11:50

In Oncology Unplugged, a podcast series from MedNews Week, host Chandler Park, MD, a medical oncologist at the Norton Cancer Institute in Louisville, Kentucky, talks through key updates in genitourinary cancer research from the 2024 ESMO Congress. In this episode, Dr Park highlights potentially practice-changing data in prostate, kidney, and bladder cancer; spotlights the potential clinical implications of findings with the intravesical therapy TAR-200 in patients with muscle-invasive bladder cancer (MIBC); and zooms in on data from the phase 3 NIAGARA trial (NCT03732677) of durvalumab (Imfinzi) plus gemcitabine and cisplatin in patients with MIBC.

data cancer congress kentucky park md louisville tar niagara esmo genitourinary mibc

Episode 360: The SUNRISE Program in Bladder Cancer

sunrise bladder cancer mibc nmibc

Play Episode Listen Later Oct 15, 2024 46:19

Christopher Cutie from J&J joins the show to discuss the SUNRISE bladder program with the gemcitabine-eluting pretzel across several NMIBC and MIBC states.

ESMO 2024 special: Results of interim analysis of SunRISe-4

Play Episode Listen Later Sep 26, 2024 10:22

UROONCO BCa chief editor Dr. Benjamin Pradere talks to Assoc. Prof. Andrea Necchi (IT) at EMSO 2024 on the results of the interim analysis of SunRISe-4 study: TAR-200 plus cetrelimab or CET alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy. Assoc. Prof. Necchi shares details of the study rationale and design, followed by an analysis of the results, and how these data could positively impact the future of treatment options for patients. According to Assoc. Prof. Necchi, the SunRISe-4 study results show for the first time that an intravesical treatment with TAR-200, combined with a systemic PD-1 inhibitor, could potentially result in a complete pathological response in a high proportion of patients.

prof sunrise pd interim tar assoc urology bladder cancer esmo mibc emso

Muscle-invasive and metastatic bladder cancer: New EAU Guidelines update

prof panel muscle guidelines invasive assoc urology metastatic bladder cancer mibc

Play Episode Listen Later Apr 27, 2024 16:21

In this special edition of EAU Podcasts, experts met in person at the EAU Annual Congress (EAU24) to discuss the newest updates to the EAU Guidelines on muscle-invasive and metastatic bladder cancer (MIBC). Panel chair Prof. J.A. Witjes led the conversation with co-chair Assoc. Prof. A. Van Der Heijden and panel member Prof. R. Cathomas to cover additions to the local imaging recommendations, restaging and new tools, systemic reviews to the guidelines, and combination therapies.

Dr. Srikala Sridhar talks about PET imaging on staging of MIBC

imaging staging urology sridhar bladder cancer esmo mibc

Play Episode Listen Later Jan 14, 2024 7:43

In this podcast, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) interviews Dr. Srikala Sridhar (CA), about her abstract she recently presented at ESMO 2023, PET-MUSE: “Impact of positron emission tomography (PET) imaging on staging of muscle-invasive bladder cancer (MIBC)”.Dr. Sridhar shares details on the rationale and design of the study, as well as some interesting results.For more details on this study, you can read this abstract on the UROONCO Bladder Cancer educational platform.

Expert Interview: Frequently Asked Questions (FAQs) for Muscle Invasive Bladder Cancer (MIBC)

ACE OncoCast

Play Episode Listen Later Nov 3, 2023 13:53 Transcription Available

Muscle-Invasive Bladder Cancer (MIBC) is defined as the tumor has spread through the bladder lining and into the bladder muscle. Optimal treatment strategies for MIBC requires the involvement of a specialist multidisciplinary team (MDT), with collaboration between surgeons, medical oncologists, radiation oncologists, pathologists and other specialists.Bladder preservation is an alternative to cystectomy for patients deemed unfit for surgery. The MDT board should develop a treatment strategy tailored to meet the needs of patients seeking bladder preservation. The management of locally advanced operable bladder cancer and the role of pre and postoperative systemic treatments have become increasingly intricate. Neoadjuvant cisplatin-based chemotherapy has been the standard of care for some years. Adjuvant immunotherapy has now emerged as a new standard of care for postoperative patients with high risks. Nonetheless, there remain gaps that need to be addressed for practicing oncologists to gain an in-depth understanding of individualized treatment strategies for MIBC.Let's watch the recorded video on 'Frequently Asked Questions (FAQs) for MIBC' to gain comprehensive insights from leading experts – Dr. Francisco X. Real from National Cancer Research Center of Spain, Dr. Félix Guerrero Ramos from Hospital Universitario 12 de Octubre in Madrid, Dr. Natalia Carballo and Dr. Enrique Grande from MD Anderson Cancer Center Madrid.

spain madrid muscle optimal faqs invasive frequently asked questions bladder mdt bladder cancer hospital universitario adjuvant neoadjuvant mibc

Episode 259: Cystectomy for bladder cancer

ananya bladder cancer mibc

Play Episode Listen Later Aug 24, 2023 25:29

Jim Catto defends the virtues of cystectomy after last weeks radiotherapy for MIBC podcast with Ananya

Special Nursing Edition — What I Tell My Patients About New Treatments and Clinical Trials in Urothelial Bladder Cancer

Oncology Today with Dr Neil Love

Play Episode Listen Later Jul 20, 2023 52:14

Dr Elizabeth Plimack from Fox Chase Cancer Center in Philadelphia, Pennsylvania, discusses available and emerging therapies for patients with urothelial bladder cancer. CME information and select publications here (https://www.researchtopractice.com/ONS2023Bladder/Audiointerview)

philadelphia pennsylvania cancer patients nursing clinical trials oncology cancer treatment chemotherapy cme ubc biomarkers immunotherapy bladder cancer new treatments fox chase cancer center mibc neil love nmibc

Global Advancements in Bladder Cancer

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 21, 2023 77:35

Based on the findings from the 2022 AUA global survey and needs assessment in bladder cancer, the AUA has developed this new series of virtual courses to update urologists on the latest advancements in bladder cancer care. This course will address new and emerging treatment options for non‐muscle invasive (NMIBC) and muscle‐invasive bladder cancer (MIBC) with a focus on identifying side effects and interventions, review of guidelines specific to first and second line therapies, timing and usage of neoadjuvant and adjuvant systemic therapy, BCG shortage and the urologists role in clinical trial enrollment. Currently available agents as well as those in development will be discussed. CME Available: https://auau.auanet.org/node/38615 ACKNOWLEDGEMENTS This educational series is supported by an independent educational grant from AstraZeneca. After participating in this educational series, participants will be able to: 1. Delineate key factors to risk stratify patients with NMIBC and MIBC. 2. Review guidelines focused on first‐ and second‐line therapies for NMIBC and MIBC. 3. Describe emerging treatment options with intravesical and systemic therapies for patients in an era of BCG shortage and for patients with BCG unresponsive disease and determine the appropriate timing and use of neoadjuvant and adjuvant systemic therapy for invasive bladder cancer. 4. Identify side effects and possible interventions to ameliorate side effects for these therapies. 5. Recognize the urologist's role in clinical trials and how to overcome obstacles to clinical trial enrollment.

global identify recognize astrazeneca advancements bcg aua bladder cancer delineate mibc nmibc

Matthew D. Galsky, MD, Neal D. Shore, MD, FACS - The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Modern Urology Practice

Play Episode Listen Later Apr 18, 2023 62:18

Go online to PeerView.com/FPT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you fully prepared as we move further into the immune checkpoint inhibitor (ICI) era in early-stage bladder cancer? Already well established in metastatic urothelial carcinoma, the role of ICIs has now been validated and resulted in regulatory approvals in both non–muscle-invasive bladder cancer (NMIBC) and high-risk muscle-invasive bladder cancer (MIBC). In this interdisciplinary discussion, two bladder cancer experts provide practical guidance on the use of ICIs in the treatment of patients with early-stage bladder cancer, including as part of bladder-sparing and perioperative approaches. Hear about accumulating evidence on these agents and learn guideline-based strategies for incorporating immunotherapy into personalized treatment plans and collaborating with other members of the cancer care team to manage immune-related adverse events and improve outcomes for your patients. Upon completion of this activity, participants should be better able to: Appraise accumulating evidence on immunotherapy strategies for bladder cancer management in early-stage disease; Incorporate approved and emerging immunotherapeutic approaches in personalized treatment plans for patients with early-stage bladder cancer, considering the available evidence, guidelines, and principles of multidisciplinary and patient-centered care; and Design and collaborate on evidence- and team-based management protocols to address the unique suite of adverse events associated with immunotherapeutic treatment options in bladder cancer.

design practice modern incorporate ici early stage urology facs readying bladder cancer appraise immuno oncology icis mibc nmibc neal d shore matthew d galsky

Matthew D. Galsky, MD, Neal D. Shore, MD, FACS - The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Modern Urology Practice

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Apr 18, 2023 62:32

Go online to PeerView.com/FPT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you fully prepared as we move further into the immune checkpoint inhibitor (ICI) era in early-stage bladder cancer? Already well established in metastatic urothelial carcinoma, the role of ICIs has now been validated and resulted in regulatory approvals in both non–muscle-invasive bladder cancer (NMIBC) and high-risk muscle-invasive bladder cancer (MIBC). In this interdisciplinary discussion, two bladder cancer experts provide practical guidance on the use of ICIs in the treatment of patients with early-stage bladder cancer, including as part of bladder-sparing and perioperative approaches. Hear about accumulating evidence on these agents and learn guideline-based strategies for incorporating immunotherapy into personalized treatment plans and collaborating with other members of the cancer care team to manage immune-related adverse events and improve outcomes for your patients. Upon completion of this activity, participants should be better able to: Appraise accumulating evidence on immunotherapy strategies for bladder cancer management in early-stage disease; Incorporate approved and emerging immunotherapeutic approaches in personalized treatment plans for patients with early-stage bladder cancer, considering the available evidence, guidelines, and principles of multidisciplinary and patient-centered care; and Design and collaborate on evidence- and team-based management protocols to address the unique suite of adverse events associated with immunotherapeutic treatment options in bladder cancer.

design practice modern incorporate ici early stage urology facs readying bladder cancer appraise immuno oncology icis mibc nmibc neal d shore matthew d galsky

Matthew D. Galsky, MD, Neal D. Shore, MD, FACS - The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Modern Urology Practice

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast

Play Episode Listen Later Apr 18, 2023 62:32

Go online to PeerView.com/FPT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you fully prepared as we move further into the immune checkpoint inhibitor (ICI) era in early-stage bladder cancer? Already well established in metastatic urothelial carcinoma, the role of ICIs has now been validated and resulted in regulatory approvals in both non–muscle-invasive bladder cancer (NMIBC) and high-risk muscle-invasive bladder cancer (MIBC). In this interdisciplinary discussion, two bladder cancer experts provide practical guidance on the use of ICIs in the treatment of patients with early-stage bladder cancer, including as part of bladder-sparing and perioperative approaches. Hear about accumulating evidence on these agents and learn guideline-based strategies for incorporating immunotherapy into personalized treatment plans and collaborating with other members of the cancer care team to manage immune-related adverse events and improve outcomes for your patients. Upon completion of this activity, participants should be better able to: Appraise accumulating evidence on immunotherapy strategies for bladder cancer management in early-stage disease; Incorporate approved and emerging immunotherapeutic approaches in personalized treatment plans for patients with early-stage bladder cancer, considering the available evidence, guidelines, and principles of multidisciplinary and patient-centered care; and Design and collaborate on evidence- and team-based management protocols to address the unique suite of adverse events associated with immunotherapeutic treatment options in bladder cancer.

design practice modern incorporate ici early stage urology facs readying bladder cancer appraise immuno oncology icis mibc nmibc neal d shore matthew d galsky

Matthew D. Galsky, MD, Neal D. Shore, MD, FACS - The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Modern Urology Practice

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Apr 18, 2023 62:18

Go online to PeerView.com/FPT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you fully prepared as we move further into the immune checkpoint inhibitor (ICI) era in early-stage bladder cancer? Already well established in metastatic urothelial carcinoma, the role of ICIs has now been validated and resulted in regulatory approvals in both non–muscle-invasive bladder cancer (NMIBC) and high-risk muscle-invasive bladder cancer (MIBC). In this interdisciplinary discussion, two bladder cancer experts provide practical guidance on the use of ICIs in the treatment of patients with early-stage bladder cancer, including as part of bladder-sparing and perioperative approaches. Hear about accumulating evidence on these agents and learn guideline-based strategies for incorporating immunotherapy into personalized treatment plans and collaborating with other members of the cancer care team to manage immune-related adverse events and improve outcomes for your patients. Upon completion of this activity, participants should be better able to: Appraise accumulating evidence on immunotherapy strategies for bladder cancer management in early-stage disease; Incorporate approved and emerging immunotherapeutic approaches in personalized treatment plans for patients with early-stage bladder cancer, considering the available evidence, guidelines, and principles of multidisciplinary and patient-centered care; and Design and collaborate on evidence- and team-based management protocols to address the unique suite of adverse events associated with immunotherapeutic treatment options in bladder cancer.

design practice modern incorporate ici early stage urology facs readying bladder cancer appraise immuno oncology icis mibc nmibc neal d shore matthew d galsky

Matthew D. Galsky, MD, Neal D. Shore, MD, FACS - The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Modern Urology Practice

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Play Episode Listen Later Apr 18, 2023 62:18

Go online to PeerView.com/FPT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you fully prepared as we move further into the immune checkpoint inhibitor (ICI) era in early-stage bladder cancer? Already well established in metastatic urothelial carcinoma, the role of ICIs has now been validated and resulted in regulatory approvals in both non–muscle-invasive bladder cancer (NMIBC) and high-risk muscle-invasive bladder cancer (MIBC). In this interdisciplinary discussion, two bladder cancer experts provide practical guidance on the use of ICIs in the treatment of patients with early-stage bladder cancer, including as part of bladder-sparing and perioperative approaches. Hear about accumulating evidence on these agents and learn guideline-based strategies for incorporating immunotherapy into personalized treatment plans and collaborating with other members of the cancer care team to manage immune-related adverse events and improve outcomes for your patients. Upon completion of this activity, participants should be better able to: Appraise accumulating evidence on immunotherapy strategies for bladder cancer management in early-stage disease; Incorporate approved and emerging immunotherapeutic approaches in personalized treatment plans for patients with early-stage bladder cancer, considering the available evidence, guidelines, and principles of multidisciplinary and patient-centered care; and Design and collaborate on evidence- and team-based management protocols to address the unique suite of adverse events associated with immunotherapeutic treatment options in bladder cancer.

design practice modern incorporate ici early stage urology facs readying bladder cancer appraise immuno oncology icis mibc nmibc neal d shore matthew d galsky

Matthew D. Galsky, MD, Neal D. Shore, MD, FACS - The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Modern Urology Practice

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Apr 18, 2023 62:32

Go online to PeerView.com/FPT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you fully prepared as we move further into the immune checkpoint inhibitor (ICI) era in early-stage bladder cancer? Already well established in metastatic urothelial carcinoma, the role of ICIs has now been validated and resulted in regulatory approvals in both non–muscle-invasive bladder cancer (NMIBC) and high-risk muscle-invasive bladder cancer (MIBC). In this interdisciplinary discussion, two bladder cancer experts provide practical guidance on the use of ICIs in the treatment of patients with early-stage bladder cancer, including as part of bladder-sparing and perioperative approaches. Hear about accumulating evidence on these agents and learn guideline-based strategies for incorporating immunotherapy into personalized treatment plans and collaborating with other members of the cancer care team to manage immune-related adverse events and improve outcomes for your patients. Upon completion of this activity, participants should be better able to: Appraise accumulating evidence on immunotherapy strategies for bladder cancer management in early-stage disease; Incorporate approved and emerging immunotherapeutic approaches in personalized treatment plans for patients with early-stage bladder cancer, considering the available evidence, guidelines, and principles of multidisciplinary and patient-centered care; and Design and collaborate on evidence- and team-based management protocols to address the unique suite of adverse events associated with immunotherapeutic treatment options in bladder cancer.

design practice modern incorporate ici early stage urology facs readying bladder cancer appraise immuno oncology icis mibc nmibc neal d shore matthew d galsky

Matthew I. Milowsky, MD, FASCO - Fresh Perspectives on Moving Toward Personalized Care for Bladder Cancer: Tips, Tools, and Strategies for Leveraging the Latest Advancements Across the Disease Spectrum

Play Episode Listen Later Mar 28, 2023 88:55

Go online to PeerView.com/KPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Management of advanced/metastatic urothelial cancer has undergone a significant transformation with the addition of PD-1– and PD-L1–targeting immune checkpoint inhibitors (ICIs) to the treatment armamentarium. These advances are quickly moving into early-stage disease, including emerging bladder-sparing and perioperative approaches, which has recently led to the first regulatory approval of an ICI as adjuvant therapy in high-risk muscle-invasive bladder cancer (MIBC). In this activity, based on a recent live symposium, experts use real-world cases and mini lectures to illustrate practical tips and treatment selection strategies for patients with MIBC or NMIBC (non–muscle-invasive bladder cancer), including clinical trial opportunities, bladder-preservation options, and perioperative regimens. This activity also examines approaches for personalized care in metastatic urothelial cancer (mUC), both in the frontline setting and in progressive disease. Upon completion of this activity, participants should be better able to: Assess new evidence on therapeutic strategies for bladder cancer management across the disease continuum based on innovative drug delivery approaches, modern immunotherapy regimens, and novel targeted agents; Implement novel and emerging therapeutic approaches into personalized treatment plans for patients with varying stages of bladder cancer considering the available evidence, current guidelines, and principles of multidisciplinary and patient-centered care; and Integrate evidence- and team-based management protocols to address the unique suite of adverse events associated with novel therapeutics for bladder cancer

Matthew I. Milowsky, MD, FASCO - Fresh Perspectives on Moving Toward Personalized Care for Bladder Cancer: Tips, Tools, and Strategies for Leveraging the Latest Advancements Across the Disease Spectrum

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Mar 28, 2023 88:44

Go online to PeerView.com/KPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Management of advanced/metastatic urothelial cancer has undergone a significant transformation with the addition of PD-1– and PD-L1–targeting immune checkpoint inhibitors (ICIs) to the treatment armamentarium. These advances are quickly moving into early-stage disease, including emerging bladder-sparing and perioperative approaches, which has recently led to the first regulatory approval of an ICI as adjuvant therapy in high-risk muscle-invasive bladder cancer (MIBC). In this activity, based on a recent live symposium, experts use real-world cases and mini lectures to illustrate practical tips and treatment selection strategies for patients with MIBC or NMIBC (non–muscle-invasive bladder cancer), including clinical trial opportunities, bladder-preservation options, and perioperative regimens. This activity also examines approaches for personalized care in metastatic urothelial cancer (mUC), both in the frontline setting and in progressive disease. Upon completion of this activity, participants should be better able to: Assess new evidence on therapeutic strategies for bladder cancer management across the disease continuum based on innovative drug delivery approaches, modern immunotherapy regimens, and novel targeted agents; Implement novel and emerging therapeutic approaches into personalized treatment plans for patients with varying stages of bladder cancer considering the available evidence, current guidelines, and principles of multidisciplinary and patient-centered care; and Integrate evidence- and team-based management protocols to address the unique suite of adverse events associated with novel therapeutics for bladder cancer

Matthew I. Milowsky, MD, FASCO - Fresh Perspectives on Moving Toward Personalized Care for Bladder Cancer: Tips, Tools, and Strategies for Leveraging the Latest Advancements Across the Disease Spectrum

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast

Play Episode Listen Later Mar 28, 2023 88:44

Go online to PeerView.com/KPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Management of advanced/metastatic urothelial cancer has undergone a significant transformation with the addition of PD-1– and PD-L1–targeting immune checkpoint inhibitors (ICIs) to the treatment armamentarium. These advances are quickly moving into early-stage disease, including emerging bladder-sparing and perioperative approaches, which has recently led to the first regulatory approval of an ICI as adjuvant therapy in high-risk muscle-invasive bladder cancer (MIBC). In this activity, based on a recent live symposium, experts use real-world cases and mini lectures to illustrate practical tips and treatment selection strategies for patients with MIBC or NMIBC (non–muscle-invasive bladder cancer), including clinical trial opportunities, bladder-preservation options, and perioperative regimens. This activity also examines approaches for personalized care in metastatic urothelial cancer (mUC), both in the frontline setting and in progressive disease. Upon completion of this activity, participants should be better able to: Assess new evidence on therapeutic strategies for bladder cancer management across the disease continuum based on innovative drug delivery approaches, modern immunotherapy regimens, and novel targeted agents; Implement novel and emerging therapeutic approaches into personalized treatment plans for patients with varying stages of bladder cancer considering the available evidence, current guidelines, and principles of multidisciplinary and patient-centered care; and Integrate evidence- and team-based management protocols to address the unique suite of adverse events associated with novel therapeutics for bladder cancer

Matthew I. Milowsky, MD, FASCO - Fresh Perspectives on Moving Toward Personalized Care for Bladder Cancer: Tips, Tools, and Strategies for Leveraging the Latest Advancements Across the Disease Spectrum

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 28, 2023 88:55

Go online to PeerView.com/KPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Management of advanced/metastatic urothelial cancer has undergone a significant transformation with the addition of PD-1– and PD-L1–targeting immune checkpoint inhibitors (ICIs) to the treatment armamentarium. These advances are quickly moving into early-stage disease, including emerging bladder-sparing and perioperative approaches, which has recently led to the first regulatory approval of an ICI as adjuvant therapy in high-risk muscle-invasive bladder cancer (MIBC). In this activity, based on a recent live symposium, experts use real-world cases and mini lectures to illustrate practical tips and treatment selection strategies for patients with MIBC or NMIBC (non–muscle-invasive bladder cancer), including clinical trial opportunities, bladder-preservation options, and perioperative regimens. This activity also examines approaches for personalized care in metastatic urothelial cancer (mUC), both in the frontline setting and in progressive disease. Upon completion of this activity, participants should be better able to: Assess new evidence on therapeutic strategies for bladder cancer management across the disease continuum based on innovative drug delivery approaches, modern immunotherapy regimens, and novel targeted agents; Implement novel and emerging therapeutic approaches into personalized treatment plans for patients with varying stages of bladder cancer considering the available evidence, current guidelines, and principles of multidisciplinary and patient-centered care; and Integrate evidence- and team-based management protocols to address the unique suite of adverse events associated with novel therapeutics for bladder cancer

Matthew I. Milowsky, MD, FASCO - Fresh Perspectives on Moving Toward Personalized Care for Bladder Cancer: Tips, Tools, and Strategies for Leveraging the Latest Advancements Across the Disease Spectrum

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 28, 2023 88:55

Go online to PeerView.com/KPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Management of advanced/metastatic urothelial cancer has undergone a significant transformation with the addition of PD-1– and PD-L1–targeting immune checkpoint inhibitors (ICIs) to the treatment armamentarium. These advances are quickly moving into early-stage disease, including emerging bladder-sparing and perioperative approaches, which has recently led to the first regulatory approval of an ICI as adjuvant therapy in high-risk muscle-invasive bladder cancer (MIBC). In this activity, based on a recent live symposium, experts use real-world cases and mini lectures to illustrate practical tips and treatment selection strategies for patients with MIBC or NMIBC (non–muscle-invasive bladder cancer), including clinical trial opportunities, bladder-preservation options, and perioperative regimens. This activity also examines approaches for personalized care in metastatic urothelial cancer (mUC), both in the frontline setting and in progressive disease. Upon completion of this activity, participants should be better able to: Assess new evidence on therapeutic strategies for bladder cancer management across the disease continuum based on innovative drug delivery approaches, modern immunotherapy regimens, and novel targeted agents; Implement novel and emerging therapeutic approaches into personalized treatment plans for patients with varying stages of bladder cancer considering the available evidence, current guidelines, and principles of multidisciplinary and patient-centered care; and Integrate evidence- and team-based management protocols to address the unique suite of adverse events associated with novel therapeutics for bladder cancer

Matthew I. Milowsky, MD, FASCO - Fresh Perspectives on Moving Toward Personalized Care for Bladder Cancer: Tips, Tools, and Strategies for Leveraging the Latest Advancements Across the Disease Spectrum

Play Episode Listen Later Mar 28, 2023 88:44

Go online to PeerView.com/KPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Management of advanced/metastatic urothelial cancer has undergone a significant transformation with the addition of PD-1– and PD-L1–targeting immune checkpoint inhibitors (ICIs) to the treatment armamentarium. These advances are quickly moving into early-stage disease, including emerging bladder-sparing and perioperative approaches, which has recently led to the first regulatory approval of an ICI as adjuvant therapy in high-risk muscle-invasive bladder cancer (MIBC). In this activity, based on a recent live symposium, experts use real-world cases and mini lectures to illustrate practical tips and treatment selection strategies for patients with MIBC or NMIBC (non–muscle-invasive bladder cancer), including clinical trial opportunities, bladder-preservation options, and perioperative regimens. This activity also examines approaches for personalized care in metastatic urothelial cancer (mUC), both in the frontline setting and in progressive disease. Upon completion of this activity, participants should be better able to: Assess new evidence on therapeutic strategies for bladder cancer management across the disease continuum based on innovative drug delivery approaches, modern immunotherapy regimens, and novel targeted agents; Implement novel and emerging therapeutic approaches into personalized treatment plans for patients with varying stages of bladder cancer considering the available evidence, current guidelines, and principles of multidisciplinary and patient-centered care; and Integrate evidence- and team-based management protocols to address the unique suite of adverse events associated with novel therapeutics for bladder cancer

Episode 229: PET in early bladder cancer - Kala Sridhar talks

sridhar bladder cancer mibc

Play Episode Listen Later Mar 20, 2023 25:43

Kala Sridhar discusses her recent PET data in MIBC

Biomarkers May Predict Neoadjuvant Chemosensitivity in Bladder Cancer

Oncotarget

Play Episode Listen Later Nov 15, 2022 8:18

Listen to a blog summary of a research paper published in Volume 13, entitled, "Predictive molecular biomarkers for determining neoadjuvant chemosensitivity in muscle invasive bladder cancer." _______________________________________________ Neoadjuvant chemotherapy (NAC) is a type of cancer treatment involving the administration of chemotherapy drugs before surgery. The goal of NAC is to shrink the tumor(s) in order to make it/them easier to remove during surgery and to decrease the chance of cancer recurrence after treatment. NAC is typically well tolerated by patients and has been shown to improve outcomes in patients with bladder cancer. Predictive biomarkers are being increasingly used in oncology to identify patients who are likely to respond to chemotherapy. In the past, the decision to administer chemotherapy was based on tumor type and stage. However, it is now understood that there is considerable heterogeneity within these groups, and that not all patients will respond to the same treatment. Predictive biomarkers can help to overcome this challenge by identifying those patients who are most likely to benefit from chemotherapy. There are a number of different types of predictive biomarkers, which can be divided into two broad categories: tumor biomarkers and host biomarkers. Tumor biomarkers are usually specific to the tumor type and can include markers of cell proliferation and DNA repair. Host biomarkers are usually found in the blood or other bodily fluids and can include markers of inflammation, immune function and metabolism. The use of predictive biomarkers has the potential to improve the efficacy of chemotherapy and reduce toxicity by avoiding its use in patients who are unlikely to benefit. In a new study, researchers Neal Murphy, Andrew J. Shih, Paras Shah, Oksana Yaskiv, Houman Khalili, Anthony Liew, Annette T. Lee, and Xin-Hua Zhu from Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health Cancer Institute, Feinstein Institutes for Medical Research, and Mayo Clinic aimed to develop and validate a predictive biomarker panel for response to NAC in patients with muscle-invasive bladder cancer (MIBC). Their research paper was published on November 2, 2022, in Oncotarget's Volume 13, entitled, “Predictive molecular biomarkers for determining neoadjuvant chemosensitivity in muscle invasive bladder cancer.” Full blog - https://www.oncotarget.org/2022/11/15/biomarkers-may-predict-neoadjuvant-chemosensitivity-in-bladder-cancer/ DOI - https://doi.org/10.18632/oncotarget.28302 Correspondence to - Neal Murphy - nmurphy2@northwell.edu, Annette T. Lee - alee@northwell.edu, and Xin-Hua Zhu - xzhu1@northwell.edu Press release - https://www.oncotarget.com/index.php?journal=oncotarget&page=news&op=press&item=oncotarget-predictive-molecular-biomarkers-for-determining-neoadjuvant-chemosensitivity-in-muscle-invasive-bladder-cancer Keywords - muscle invasive bladder cancer, neoadjuvant chemotherapy, gene expression, molecular subtyping, canonical correlation analysis About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/OncotargetYouTube LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/

Urothelial Bladder Cancer | Oncology Today with Dr Neil Love: Management of Nonmetastatic Urothelial Bladder Cancer

management treatments clinical oncology dispelling bcg cme bladder cancer neoadjuvant mibc nmibc neil love

Play Episode Listen Later Oct 20, 2022 46:18

Featuring an interview with Prof Sia Daneshmand, including the following topics: Clinical presentation and initial evaluation of non-muscle-invasive urothelial bladder cancer (NMIBC) (0:00) Alternative induction regimens when BCG is not available (4:06) Treatment options for patients with BCG-refractory disease (8:46) Role of immunotherapy in treating NMIBC (13:58) Role of cystectomy in treating NMIBC (15:47) Intravesical drug delivery for patients with muscle-invasive urothelial bladder cancer (MIBC) (20:37) Dispelling myths and misperceptions about cystectomy and counseling eligible patients (26:19) Neoadjuvant and adjuvant therapy for MIBC (37:40) CME information and select publications

Urothelial Bladder Cancer | Oncology Today with Dr Neil Love: Management of Nonmetastatic Urothelial Bladder Cancer (Companion Faculty Lecture)

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 20, 2022 27:18

Featuring a slide presentation and related discussion from Prof Sia Daneshmand, including the following topics: Continuous intravesical drug delivery for patients with muscle-invasive urothelial bladder cancer (MIBC) (0:00) Current role of checkpoint inhibitors alone or in combination with chemotherapy for urothelial bladder cancer (UBC) (9:26) Emerging data with novel agents and strategies for the management of UBC (14:52) Case: A man in his mid 70s with a history of high-grade T1 disease who is not a good candidate for cystectomy (18:57) Case: A man in his early 80s with high-grade T2 MIBC who is not a candidate for cystectomy or neoadjuvant chemotherapy (22:27) Case: A woman in her late 50s with completely resected UBC with a strong preference for bladder-sparing treatment (24:43) CME information and select publications

management current emerging faculty lecture companion continuous oncology cme ubc t1 bladder cancer mibc neil love

Ashish M. Kamat, MD, MBBS - Transforming Bladder Cancer Treatment: Essential Guidance for Urologists on Therapeutic Selection, Safety, and Sequencing Along the Disease Continuum

Play Episode Listen Later Jul 22, 2022 60:38

Go online to PeerView.com/RMY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, the research on actionable targets in bladder cancer has led to regulatory approval of the FGFR-targeted therapy erdafitinib for FGFR mutation-positive bladder tumors, and antibody–drug conjugates (ADCs). Additional advances have occurred in the localized disease setting such as novel bladder-sparing and perioperative approaches, as well as the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. Further, important combination approaches expand the therapeutic capacity available to patients with bladder cancer. This CME-certified activity will highlight strategies for optimal care for managing patients with bladder cancer in light of current evidence and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Identify patients with early-stage bladder cancer who could potentially benefit from the use of novel therapeutic strategies in the adjuvant and neoadjuvant settings (ie, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials; Integrate therapeutic strategies into management protocols for eligible patients with metastatic bladder cancer based on regulatory status and treatment roles of emerging therapeutic classes (ie, immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates), including in the context of clinical trials; Develop appropriate strategies to mitigate and manage the unique adverse events associated with the variety of novel and emerging therapeutic classes for the management of bladder cancer.

Ashish M. Kamat, MD, MBBS - Transforming Bladder Cancer Treatment: Essential Guidance for Urologists on Therapeutic Selection, Safety, and Sequencing Along the Disease Continuum

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 22, 2022 60:29

Go online to PeerView.com/RMY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, the research on actionable targets in bladder cancer has led to regulatory approval of the FGFR-targeted therapy erdafitinib for FGFR mutation-positive bladder tumors, and antibody–drug conjugates (ADCs). Additional advances have occurred in the localized disease setting such as novel bladder-sparing and perioperative approaches, as well as the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. Further, important combination approaches expand the therapeutic capacity available to patients with bladder cancer. This CME-certified activity will highlight strategies for optimal care for managing patients with bladder cancer in light of current evidence and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Identify patients with early-stage bladder cancer who could potentially benefit from the use of novel therapeutic strategies in the adjuvant and neoadjuvant settings (ie, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials; Integrate therapeutic strategies into management protocols for eligible patients with metastatic bladder cancer based on regulatory status and treatment roles of emerging therapeutic classes (ie, immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates), including in the context of clinical trials; Develop appropriate strategies to mitigate and manage the unique adverse events associated with the variety of novel and emerging therapeutic classes for the management of bladder cancer.

Ashish M. Kamat, MD, MBBS - Transforming Bladder Cancer Treatment: Essential Guidance for Urologists on Therapeutic Selection, Safety, and Sequencing Along the Disease Continuum

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 22, 2022 60:29

Go online to PeerView.com/RMY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, the research on actionable targets in bladder cancer has led to regulatory approval of the FGFR-targeted therapy erdafitinib for FGFR mutation-positive bladder tumors, and antibody–drug conjugates (ADCs). Additional advances have occurred in the localized disease setting such as novel bladder-sparing and perioperative approaches, as well as the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. Further, important combination approaches expand the therapeutic capacity available to patients with bladder cancer. This CME-certified activity will highlight strategies for optimal care for managing patients with bladder cancer in light of current evidence and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Identify patients with early-stage bladder cancer who could potentially benefit from the use of novel therapeutic strategies in the adjuvant and neoadjuvant settings (ie, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials; Integrate therapeutic strategies into management protocols for eligible patients with metastatic bladder cancer based on regulatory status and treatment roles of emerging therapeutic classes (ie, immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates), including in the context of clinical trials; Develop appropriate strategies to mitigate and manage the unique adverse events associated with the variety of novel and emerging therapeutic classes for the management of bladder cancer.

Ashish M. Kamat, MD, MBBS - Transforming Bladder Cancer Treatment: Essential Guidance for Urologists on Therapeutic Selection, Safety, and Sequencing Along the Disease Continuum

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 22, 2022 60:29

Go online to PeerView.com/RMY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, the research on actionable targets in bladder cancer has led to regulatory approval of the FGFR-targeted therapy erdafitinib for FGFR mutation-positive bladder tumors, and antibody–drug conjugates (ADCs). Additional advances have occurred in the localized disease setting such as novel bladder-sparing and perioperative approaches, as well as the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. Further, important combination approaches expand the therapeutic capacity available to patients with bladder cancer. This CME-certified activity will highlight strategies for optimal care for managing patients with bladder cancer in light of current evidence and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Identify patients with early-stage bladder cancer who could potentially benefit from the use of novel therapeutic strategies in the adjuvant and neoadjuvant settings (ie, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials; Integrate therapeutic strategies into management protocols for eligible patients with metastatic bladder cancer based on regulatory status and treatment roles of emerging therapeutic classes (ie, immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates), including in the context of clinical trials; Develop appropriate strategies to mitigate and manage the unique adverse events associated with the variety of novel and emerging therapeutic classes for the management of bladder cancer.

Ashish M. Kamat, MD, MBBS - Transforming Bladder Cancer Treatment: Essential Guidance for Urologists on Therapeutic Selection, Safety, and Sequencing Along the Disease Continuum

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 22, 2022 60:38

Go online to PeerView.com/RMY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, the research on actionable targets in bladder cancer has led to regulatory approval of the FGFR-targeted therapy erdafitinib for FGFR mutation-positive bladder tumors, and antibody–drug conjugates (ADCs). Additional advances have occurred in the localized disease setting such as novel bladder-sparing and perioperative approaches, as well as the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. Further, important combination approaches expand the therapeutic capacity available to patients with bladder cancer. This CME-certified activity will highlight strategies for optimal care for managing patients with bladder cancer in light of current evidence and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Identify patients with early-stage bladder cancer who could potentially benefit from the use of novel therapeutic strategies in the adjuvant and neoadjuvant settings (ie, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials; Integrate therapeutic strategies into management protocols for eligible patients with metastatic bladder cancer based on regulatory status and treatment roles of emerging therapeutic classes (ie, immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates), including in the context of clinical trials; Develop appropriate strategies to mitigate and manage the unique adverse events associated with the variety of novel and emerging therapeutic classes for the management of bladder cancer.

Ashish M. Kamat, MD, MBBS - Transforming Bladder Cancer Treatment: Essential Guidance for Urologists on Therapeutic Selection, Safety, and Sequencing Along the Disease Continuum

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 22, 2022 60:38

Go online to PeerView.com/RMY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, the research on actionable targets in bladder cancer has led to regulatory approval of the FGFR-targeted therapy erdafitinib for FGFR mutation-positive bladder tumors, and antibody–drug conjugates (ADCs). Additional advances have occurred in the localized disease setting such as novel bladder-sparing and perioperative approaches, as well as the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. Further, important combination approaches expand the therapeutic capacity available to patients with bladder cancer. This CME-certified activity will highlight strategies for optimal care for managing patients with bladder cancer in light of current evidence and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Identify patients with early-stage bladder cancer who could potentially benefit from the use of novel therapeutic strategies in the adjuvant and neoadjuvant settings (ie, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials; Integrate therapeutic strategies into management protocols for eligible patients with metastatic bladder cancer based on regulatory status and treatment roles of emerging therapeutic classes (ie, immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates), including in the context of clinical trials; Develop appropriate strategies to mitigate and manage the unique adverse events associated with the variety of novel and emerging therapeutic classes for the management of bladder cancer.

Ashish M. Kamat, MD, MBBS - Transforming Bladder Cancer Treatment: Essential Guidance for Urologists on Therapeutic Selection, Safety, and Sequencing Along the Disease Continuum

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 22, 2022 60:38

Go online to PeerView.com/RMY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, the research on actionable targets in bladder cancer has led to regulatory approval of the FGFR-targeted therapy erdafitinib for FGFR mutation-positive bladder tumors, and antibody–drug conjugates (ADCs). Additional advances have occurred in the localized disease setting such as novel bladder-sparing and perioperative approaches, as well as the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. Further, important combination approaches expand the therapeutic capacity available to patients with bladder cancer. This CME-certified activity will highlight strategies for optimal care for managing patients with bladder cancer in light of current evidence and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Identify patients with early-stage bladder cancer who could potentially benefit from the use of novel therapeutic strategies in the adjuvant and neoadjuvant settings (ie, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials; Integrate therapeutic strategies into management protocols for eligible patients with metastatic bladder cancer based on regulatory status and treatment roles of emerging therapeutic classes (ie, immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates), including in the context of clinical trials; Develop appropriate strategies to mitigate and manage the unique adverse events associated with the variety of novel and emerging therapeutic classes for the management of bladder cancer.

Ashish M. Kamat, MD, MBBS - Transforming Bladder Cancer Treatment: Essential Guidance for Urologists on Therapeutic Selection, Safety, and Sequencing Along the Disease Continuum

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 22, 2022 60:29

Go online to PeerView.com/RMY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, the research on actionable targets in bladder cancer has led to regulatory approval of the FGFR-targeted therapy erdafitinib for FGFR mutation-positive bladder tumors, and antibody–drug conjugates (ADCs). Additional advances have occurred in the localized disease setting such as novel bladder-sparing and perioperative approaches, as well as the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. Further, important combination approaches expand the therapeutic capacity available to patients with bladder cancer. This CME-certified activity will highlight strategies for optimal care for managing patients with bladder cancer in light of current evidence and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Identify patients with early-stage bladder cancer who could potentially benefit from the use of novel therapeutic strategies in the adjuvant and neoadjuvant settings (ie, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials; Integrate therapeutic strategies into management protocols for eligible patients with metastatic bladder cancer based on regulatory status and treatment roles of emerging therapeutic classes (ie, immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates), including in the context of clinical trials; Develop appropriate strategies to mitigate and manage the unique adverse events associated with the variety of novel and emerging therapeutic classes for the management of bladder cancer.

Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the Community

Play Episode Listen Later Jun 14, 2022 81:08

Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.

community patients develop guidance clinical utilizing select implement realistic pd translating patient care employ multidisciplinary ashish mbbs consults bladder cancer pd l1 fgfr therapeutic advances mibc nmibc this peerview clinical consults

Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the Community

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 14, 2022 81:18

Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.

community patients develop guidance clinical utilizing select implement realistic pd translating patient care employ multidisciplinary ashish mbbs consults bladder cancer pd l1 fgfr therapeutic advances mibc nmibc this peerview clinical consults

Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the Community

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 14, 2022 81:08

Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.

community patients develop guidance clinical utilizing select implement realistic pd translating patient care employ multidisciplinary ashish mbbs consults bladder cancer pd l1 fgfr therapeutic advances mibc nmibc this peerview clinical consults

Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the Community

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 14, 2022 81:08

Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.

community patients develop guidance clinical utilizing select implement realistic pd translating patient care employ multidisciplinary ashish mbbs consults bladder cancer pd l1 fgfr therapeutic advances mibc nmibc this peerview clinical consults

Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the Community

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 14, 2022 81:08

Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.

community patients develop guidance clinical utilizing select implement realistic pd translating patient care employ multidisciplinary ashish mbbs consults bladder cancer pd l1 fgfr therapeutic advances mibc nmibc this peerview clinical consults

Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the Community

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 14, 2022 81:18

Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.

community patients develop guidance clinical utilizing select implement realistic pd translating patient care employ multidisciplinary ashish mbbs consults bladder cancer pd l1 fgfr therapeutic advances mibc nmibc this peerview clinical consults

Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the Community

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 14, 2022 81:18

Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.

community patients develop guidance clinical utilizing select implement realistic pd translating patient care employ multidisciplinary ashish mbbs consults bladder cancer pd l1 fgfr therapeutic advances mibc nmibc this peerview clinical consults

Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the Community

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 14, 2022 81:18

Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.

community patients develop guidance clinical utilizing select implement realistic pd translating patient care employ multidisciplinary ashish mbbs consults bladder cancer pd l1 fgfr therapeutic advances mibc nmibc this peerview clinical consults

Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the Community

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 14, 2022 81:18

Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.

community patients develop guidance clinical utilizing select implement realistic pd translating patient care employ multidisciplinary ashish mbbs consults bladder cancer pd l1 fgfr therapeutic advances mibc nmibc this peerview clinical consults

Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the Community

Katheterkollegen - der Urologie Podcast

Play Episode Listen Later Jun 14, 2022 81:08

Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.

community patients develop guidance clinical utilizing select implement realistic pd translating patient care employ multidisciplinary ashish mbbs consults bladder cancer pd l1 fgfr therapeutic advances mibc nmibc this peerview clinical consults

Post ASCO GU '22 – Muscle-Invasive Bladder Cancer, EV-103, Enfortumab Vedotin, and the Clinical Progress Being Made Managing MIBC Patients

OBR Peer-Spectives

Play Episode Listen Later Mar 7, 2022 9:41

Daniel Petrylak, MD, Professor of Medicine at the Yale Cancer Center, and Robert Figlin, MD, of Cedars-Sinai Cancer discuss recent developments at ASCO GU in muscle-invasive bladder cancer and in particular the EV-103 clinical study while also discussing the future of MIBC treatment.

professor managing medicine progress patients md muscle ev clinical invasive bladder cancer yale cancer center asco gu mibc daniel petrylak

No Bladder, No Cry - die Zystektomie

Play Episode Listen Later Dec 19, 2021 66:45

"Wann empfiehlt man eigentlich ein Ileum-Conduit und wann eine Neoblase?", "Wie zeichne ich das Conduit richtig an?" und "Woran muss ich denken, wenn es nach der Zystektomie zu Komplikationen kommt?" - Diese und viele weitere Fragen rund um die Zystektomie beantworten die beiden Experten Prof. Alexander Karl (München) und Prof. Günter Niegisch (Düsseldorf). Die Folge steckt voller Praxistipps und Tricks zum Umgang mit Patient:innen nach Zystektomie. Wir wünschen Euch viel Spaß beim Zuhören!

patients prof spa tricks diese umgang wann woran die folge bladder conduit urology chirurgie komplikationen praxistipps bladder cancer urologie experten prof mibc

#045 Bladder preservation for MIBC

EMPIRE Urology Podcast

Play Episode Listen Later Sep 27, 2021 51:22

Dr. Richard Matulewicz MD discusses bladder preservation strategies for muscle invasive bladder cancer 5/15/20

preservation bladder mibc

Genitourinary Cancers | Oncology Today with Dr Neil Love: Key Presentations on Genitourinary Cancers from the 2021 ASCO Annual Meeting